A randomized, double-blind, placebo-controlled parallel group study published in this month’s issue of the European Journal of Pain, and published online early by the National Institute of Health, has found that cannabis can significantly reduce pain and improve sleep in those with neuropathic pain.
For the study; “303 patients with PNP (peripheral neuropathic pain) associated with allodynia were screened; 128 were randomized to THC/CBD spray and 118 to placebo, in addition to their current analgesic therapy.”
After conducting the study, which used a spray made from THC (tetrahydrocannabinol) and CBD (cannabidiol), both compounds of cannabis, researchers found that “a meaningful proportion of otherwise treatment-resistant patients, clinically important improvements in pain, sleep quality and SGIC of the severity of their condition are obtained with THC/CBD spray. THC/CBD spray was well tolerated and no new safety concerns were identified.”
The study, which was conducted by researchers a Gartnavel General Hospital at the University of Glasgow in the U.K., can be found by clicking here.
